Good morning, Jason Mast here filling in for Ed. Happy turkey week to all. I, for one, have always detested that dry, tasteless bird. (It’s sides and brisket for me, followed by pecan pie.) So in their interest, I leave you with this story, from 2018, about the Ozark turkeys that fell from the sky. A trajectory not unlike Novo Nordisk’s stock, after today’s news. …
Novo Nordisk’s weight loss drug semaglutide failed to slow the progression of Alzheimer’s disease in two large trials, STAT reports. The results will, for now, quiet excitement around a darkhorse theory for treating Alzheimer’s that had percolated over the last few years, based on retrospective studies that suggested patients taking the drug had lower risk of dementia, possibly because it dampened inflammation. Executives at Novo, which is down 10% today, had long warned the studies were risky.
STAT Pharma: The science and business of new drug development
Leave a Reply